ALB Evaluation for NOAA charting requirements

The National Oceanic and Atmospheric Administration (NOAA) acquires hydrographic data around the coasts of the US and its territories using in-house surveys and contracting resources. Hydrographic data are primarily collected using sonar systems, while a small percent is acquired via Airborne Lidar Bathymetry (ALB) for nearshore areas. NOAA has an ongoing requirement, as per the Coast and Geodetic Survey Act of 1947, to survey nearshore areas as part of its coastal mapping activities, including updating nautical charts, creating hydrodynamic models and supporting coastal planning and habitat mapping. NOAA has initiated a project to investigate the potential use of ALB data from non-hydrographic survey programmes (i.e., programmes designed to support objectives other than nautical charting and with specifications and requirements that differ from those of NOAA hydrographic surveys) in order to increase the amount of data available to meet these nearshore mapping requirements. THIS PAPER PRESENTS AN evaluation of ALB data from the US Army Corps of Engineers (USACE) National Coastal Mapping Program (NCMP) for use by NOAA’s Offi ce of Coast Survey (OCS). Th ese NCMP datasets were evaluated through a statistical comparison to bathymetric surfaces derived from hydrographic NOAA surveys. Th e objectives of the analysis were: 1. to assess the level of agreement between the NCMP and OCS data in areas of overlap in a variety of coastal environments and 2. to determine whether NCMP ALB survey data can be compiled with NOAA OCS hydrographic data to generate seamless shallowbathymetry digital elevation modes (DEMs)

Clinical Research Challenges: Insight from a Pilot Study at an Academic Healthcare Center

An investigational clinical research study was conducted at an academic healthcare center evaluating memantine as an adjunct to opioid therapy for treatment of chronic low back pain. The N-Methyl-D-Aspartate (NMDA) receptor is located in pain signaling neuronal synapses of the central nervous system. The receptor binds the excitatory neurotransmitter glutamate in addition to NMDA, to increase the magnitude of the perception of pain. Memantine (Namenda©) is a highly tolerated NMDA receptor antagonist which is currently prescribed in the treatment of Alzheimer’s disease. The purpose of the non-randomized pilot study without placebo was to evaluate the use of adding memantine as an adjunctive pain medication to the regimen of patients who use an oxycodone/acetaminophen combination daily for treatment of chronic low back pain (LBP). The effect of Memantine was evaluated using diaries where patients record on a daily basis the amount of oxycodone/acetaminophen used, pain scores, and number of bowel movements. Data was to be collected for six weeks with a two-week preliminary phase, followed by a four-week treatment phase, and then analyzed. The objective is to evaluate, on a preliminary basis, whether patients benefit from addition of memantine to their daily oxycodone/acetaminophen treatment by increased analgesia, a reduction of oxycodone/acetaminophen used, and less constipation. Consequently, limitations to the process of clinical research in an academic healthcare center are evaluated as a result of reduced protected time for researchers and lack of patient participation

The Acquisition of Human B Cell Memory in Response to Plasmodium Falciparum Malaria

Immunity to Plasmodium falciparum (Pf), the most deadly agent of malaria, is only acquired after years of repeated infections and appears to wane rapidly without ongoing exposure. Antibodies (Abs) are central to malaria immunity, yet little is known about the B‐cell biology that underlies Pf‐specific humoral immunity. To address this gap in our knowledge we carried out a year‐long prospective study of the acquisition and maintenance of long‐lived plasma cells (LLPCs) and memory B cells (MBCs) in 225 individuals aged two to twenty‐five years in Mali, in an area of intense seasonal transmission. Using protein microarrays containing approximately 25% of the Pf proteome we determined that Pf‐specific Abs were acquired only gradually, in a stepwise fashion over years of Pf exposure. Pf‐specific Ab levels were significantly boosted each year during the transmission season but the majority of these Abs were short lived and were lost over the subsequent six month period of no transmission. Thus, we observed only a small incremental increase in stable Ab levels each year, presumably reflecting the slow acquisition LLPCs. The acquisition Pf‐specific MBCs mirrored the slow step‐wise acquisition of LLPCs. This slow acquisition of Pf‐specific LLPCs and MBCs was in sharp contrast to that of tetanus toxoid (TT)‐specific LLPCs and MBCs that were vi vi rapidly acquired and stably maintained following a single vaccination in individuals in this cohort. In addition to the development of normal MBCs we observed an expansion of atypical MBCs that are phenotypically similar to hyporesponsive FCRL4+ cells described in HIV‐infected individuals. Atypical MBC expansion correlated with cumulative exposure to Pf, and with persistent asymptomatic Pf‐infection in children, suggesting that the parasite may play a role in driving the expansion of atypical MBCs. Collectively, these observations provide a rare glimpse into the process of the acquisition of human B cell memory in response to infection and provide evidence for a selective deficit in the generation of Pf‐specific LLPCs and MBCs during malaria. Future studies will address the mechanisms underlying the slow acquisition of LLPCs and MBCs and the generation and function of atypical MBCs